Tradename | Company | Number | Date | Products |
---|---|---|---|---|
AZACITIDINE | Allergan | N-208216 RX | 2016-04-29 | 1 products |
ONUREG | Bristol Myers Squibb | N-214120 RX | 2020-09-01 | 2 products, RLD, RS |
VIDAZA | Bristol Myers Squibb | N-050794 RX | 2004-05-19 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
azacitidine | ANDA | 2025-02-06 |
azacitidine for | ANDA | 2022-09-14 |
onureg | New Drug Application | 2022-10-26 |
vidaza | New Drug Application | 2024-01-29 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
myelomonocytic leukemia chronic | — | D015477 | C93.1 |
sideroblastic anemia | — | D000756 | D64.3 |
refractory anemia | — | D000753 | D46.4 |
Expiration | Code | ||
---|---|---|---|
AZACITIDINE, VIDAZA, BRISTOL-MYERS | |||
2029-05-20 | ODE-399 | ||
2025-05-20 | I-889 | ||
AZACITIDINE, ONUREG, BRISTOL | |||
2027-09-01 | ODE-320 |
Code | Description |
---|---|
J9025 | Injection, azacitidine, 1 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Myelodysplastic syndromes | D009190 | — | D46 | 2 | 3 | 1 | — | 1 | 5 |
Preleukemia | D011289 | — | — | 2 | 3 | 1 | — | 1 | 5 |
Syndrome | D013577 | — | — | 2 | 2 | 1 | — | 1 | 4 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Leukemia | D007938 | — | C95 | 2 | 5 | — | — | 3 | 9 |
Myeloid leukemia acute | D015470 | — | C92.0 | 2 | 3 | — | — | 3 | 8 |
Myeloid leukemia | D007951 | — | C92 | 1 | 3 | — | — | 3 | 7 |
Non-small-cell lung carcinoma | D002289 | — | — | — | 2 | — | — | — | 2 |
Pathologic complete response | D000095384 | — | — | — | 2 | — | — | — | 2 |
Melanoma | D008545 | — | — | — | 1 | — | — | — | 1 |
Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 1 | 1 | — | — | — | 1 |
Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | 1 | 1 | — | — | — | 1 |
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | 1 | — | — | — | 1 |
Recurrence | D012008 | — | — | 1 | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Liver failure | D017093 | — | K72.9 | 1 | — | — | — | — | 1 |
Neoplasms | D009369 | — | C80 | 1 | — | — | — | — | 1 |
Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Myelomonocytic leukemia chronic | D015477 | — | C93.1 | — | — | — | — | 1 | 1 |
Myelomonocytic leukemia juvenile | D054429 | — | C93.3 | — | — | — | — | 1 | 1 |
Drug common name | Azacitidine |
INN | azacitidine |
Description | 5-azacytidine is an N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia. It has a role as an antineoplastic agent. It is a N-glycosyl-1,3,5-triazine and a nucleoside analogue. It is functionally related to a beta-D-ribose. |
Classification | Small molecule |
Drug class | H2-receptor antagonists (cimetidine type) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 |
PDB | — |
CAS-ID | 320-67-2 |
RxCUI | — |
ChEMBL ID | CHEMBL1489 |
ChEBI ID | 2038 |
PubChem CID | 9444 |
DrugBank | DB00928 |
UNII ID | M801H13NRU (ChemIDplus, GSRS) |